

Supplementary Material

Table S4

Factors associated with risk of liver enzyme elevation >3.5 times than baseline levels– results from multivariable analyses among HCV-Ab negative and HCV-Ab positive subjects

	HCV-Ab negative HR (95%CI)	HCV-Ab positive HR (95%CI)
Age (per 10 years increase)	0.98 (0.86-1.12)	0.79 (0.68-0.91)
Male gender	1.1 (0.83-1.47)	1.12 (0.9-1.4)
Italian born	0.58 (0.44-0.75)	0.75 (0.55-1.03)
Route of HIV transmission		
Intravenous drug use	1	1
Homosexual intercourse	0.89 (0.52-1.52)	1 (0.65-1.53)
Heterosexual intercourse	0.63 (0.37-1.05)	1.35 (1.05-1.73)
Other/Unknown	0.78 (0.42-1.45)	1.35 (0.93-1.95)
HBs-Ag positivity	1.1 (0.71-1.72)	1.03 (0.75-1.43)
Previously naïve to antiretrovirals	1.06 (0.77-1.72)	1.91 (1.52-2.41)
Calendar year at study treatment initiation		
1998-2004	1	1
2005-2008	0.96 (0.69-1.34)	0.89 (0.72-1.1)
2019-2012	0.97 (0.64-1.49)	0.63 (0.44-0.91)
Type of PI/r used		
Lopinavir/ritonavir	1	1
Atazanavir/ritonavir	1.04 (0.78-1.4)	1.05 (0.85-1.31)
Darunavir/ritonavir 800/100 mg once-daily	0.7 (0.35-1.41)	1.21 (0.62-2.36)
Darunavir/ritonavir 600/100 mg twice-daily	0.78 (0.41-1.48)	0.68 (0.36-1.28)
Fosamprenavir/ritonavir	0.71 (0.43-1.18)	0.95 (0.69-1.31)
Other	1.27 (0.82-1.96)	1.02 (0.79-1.32)
NNRTI co-administration	1.17 (0.66-2.06)	1.63 (1.17-2.28)
Baseline CD4+ (per 50 cells/mm ³ increase)	0.97 (0.94-0.99)	0.97 (0.95-0.99)
Body mass index (m ² /Kg)		
Normal (18.5-24.9)	1	1
Underweight (<18.5)	1.11 (0.6-2.06)	0.98 (0.68-1.4)
Overweight (25-30)	0.75 (0.52-1.08)	0.98 (0.77-1.25)
Obese (>30)	1.41 (0.93-2.12)	1.19 (0.77-1.85)

Abbreviations: AST, aspartate amino-transferase; CI, confidence interval; HBsAg, hepatitis B surface antigen; HCV-Ab, hepatitis C virus antibodies; HR, hazard ratio; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI/r, boosted-protease inhibitors.